Avai Bio (AVAI) Capital Expenditures (2018 - 2021)

Avai Bio (AVAI) has 3 years of Capital Expenditures data on file, last reported at -$122817.0 in Q1 2021.

• For the quarter ending Q1 2021, Capital Expenditures fell 9439.7% year-over-year to -$122817.0; the trailing twelve-month figure through Mar 2021 stood at $114.0 (down 91.33% YoY), and the FY2021 full-year result was $114.0, down 91.33% from the prior year.
• Capital Expenditures eased to -$122817.0 in Q1 2021, from $122550.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $122550.0 in Q4 2020 to a low of -$122817.0 in Q1 2021.
• A 3-year average of $4544.5 and a median of $958.0 in 2020 frame the typical range for Capital Expenditures.
• Peak annual rise in Capital Expenditures reached 9439.7% in 2021, while the deepest fall reached 9439.7% in 2021.
• Tracing AVAI's Capital Expenditures over 3 years: stood at $25838.0 in 2018, then jumped by 374.3% to $122550.0 in 2020, then slumped by 200.22% to -$122817.0 in 2021.
• Business Quant data shows AVAI's Capital Expenditures at -$122817.0 in Q1 2021, $122550.0 in Q4 2020, and $601.0 in Q3 2020.